Capricor Therapeutics, Inc.

CAPR Healthcare Biotechnology

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.

6.95 0.52 −6.96%
Market cap
$434.3M
P/E
0.0×
Fwd P/E
−13.2×
Dividend yield
—
F-score
4/9
Altman Z
10.32
Beneish M
−2.61
Dividend safety
n/a

Capricor Therapeutics, Inc. (CAPR) P/E ratio

Alert me on P/E ratio

Capricor Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 69.7× (January 2018) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 52.3× —
FY2016 0.0× —
FY2015 0.0× —

Quarterly newest first

Period P/E ratio Change
Dec 2024 0.0× —
Sep 2024 0.0× —
Jun 2024 0.0× —
Mar 2024 0.0× —
33 more quarters

Against its own ten years

Low 0.0× High 69.7×
Ten-year median 0.0×
Current reading's percentile 92

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CAPR